No Data
No Data
Hold Rating on Cogent Biosciences Amid Competitive Landscape and Anticipated Milestones
Cogent Biosciences Is Maintained at Overweight by JP Morgan
JP Morgan Maintains Overweight on Cogent Biosciences, Lowers Price Target to $19
Cogent Biosciences Price Target Maintained With a $18.00/Share by Needham
Express News | 5Needham Reiterates Buy on Cogent Biosciences, Maintains $18 Price Target
Express News | Cogent Biosciences Inc : JP Morgan Cuts Target Price to $19 From $22
No Data